GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells
暂无分享,去创建一个
R. Henrique | C. Jerónimo | A. M. Araújo | P. Guedes de Pinho | M. Bastos | A. R. Lima | J. Pinto | M. Carvalho
[1] Xin Lu,et al. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method , 2017, Oncotarget.
[2] Maria de Lourdes Bastos,et al. Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies , 2016, Translational oncology.
[3] C. Barbas,et al. From sample treatment to biomarker discovery: A tutorial for untargeted metabolomics based on GC-(EI)-Q-MS. , 2015, Analytica chimica acta.
[4] P. Ditonno,et al. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer , 2015, Expert review of molecular diagnostics.
[5] Roman Kaliszan,et al. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study. , 2015, Journal of pharmaceutical and biomedical analysis.
[6] M. Gleave,et al. Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development , 2015, The Journal of pathology.
[7] Ashish Gupta,et al. Metabolomics-derived prostate cancer biomarkers: fact or fiction? , 2015, Journal of proteome research.
[8] A. Halama. Metabolomics in cell culture--a strategy to study crucial metabolic pathways in cancer development and the response to treatment. , 2014, Archives of biochemistry and biophysics.
[9] F. Baltazar,et al. Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know? , 2014, International journal of molecular sciences.
[10] Alessandro Larcher,et al. Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature , 2014, Korean journal of urology.
[11] Alexander G. Gray,et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. , 2014, Journal of proteome research.
[12] M. Koutsilieris,et al. Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up , 2014, BioMed research international.
[13] Leo L. Cheng,et al. High‐resolution magic angle spinning 1H MRS in prostate cancer , 2014, NMR in biomedicine.
[14] G. Kristiansen,et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma , 2013, International journal of cancer.
[15] Yair Lotan,et al. Metabolomic signatures of aggressive prostate cancer , 2013, The Prostate.
[16] Rawi Ramautar,et al. Human metabolomics: strategies to understand biology. , 2013, Current opinion in chemical biology.
[17] John Kurhanewicz,et al. Metabolic Reprogramming and Validation of Hyperpolarized 13C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor , 2013, The Prostate.
[18] V. Adam,et al. Sarcosine as a Potential Prostate Cancer Biomarker—A Review , 2013, International journal of molecular sciences.
[19] C. Cooper,et al. The Present and Future of Prostate Cancer Urine Biomarkers , 2013, International journal of molecular sciences.
[20] Anastasia K Yocum,et al. The role of sarcosine metabolism in prostate cancer progression. , 2013, Neoplasia.
[21] D. Wishart,et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.
[22] David S. Wishart,et al. HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..
[23] Charles Pound,et al. Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics , 2012, PloS one.
[24] N. Teixeira,et al. A gas chromatography-mass spectrometry multi-target method for the simultaneous analysis of three classes of metabolites in marine organisms. , 2012, Talanta.
[25] S. Sereika,et al. Effect size estimation: methods and examples. , 2012, International journal of nursing studies.
[26] Edward D. Karoly,et al. Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer , 2012, Clinical Cancer Research.
[27] Takashi Ishikawa,et al. Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.
[28] Bruce J Trock,et al. Application of metabolomics to prostate cancer. , 2011, Urologic oncology.
[29] Giuseppe Gallone,et al. Bio::Homology::InterologWalk - A Perl module to build putative protein-protein interaction networks through interolog mapping , 2011, BMC Bioinformatics.
[30] A. Shojaie,et al. Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.
[31] H. Keun,et al. Metabolic signatures of malignant progression in prostate epithelial cells. , 2011, The international journal of biochemistry & cell biology.
[32] Tao-Tao Liu,et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization , 2011, Analytical and bioanalytical chemistry.
[33] Kurt Miller,et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. , 2011, The Journal of urology.
[34] Pär Stattin,et al. Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol , 2010, PloS one.
[35] M. Čuperlović-Culf,et al. Cell culture metabolomics: applications and future directions. , 2010, Drug discovery today.
[36] G. Kristiansen,et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.
[37] David S. Wishart,et al. MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data , 2010, Nucleic Acids Res..
[38] J. Céraline,et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line , 2010, Human mutation.
[39] D. Kufe,et al. Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.
[40] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[41] E. Riboli,et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. , 2008, The American journal of clinical nutrition.
[42] David S. Wishart,et al. HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..
[43] P. Carroll,et al. Quantification of choline‐ and ethanolamine‐containing metabolites in human prostate tissues using 1H HR‐MAS total correlation spectroscopy , 2008, Magnetic resonance in medicine.
[44] D. Ponde,et al. Comparison of radiolabeled choline and ethanolamine as probe for cancer detection , 2008, Cancer biology & therapy.
[45] M. Tisdale,et al. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. , 2007, American journal of physiology. Endocrinology and metabolism.
[46] Ying Zhang,et al. HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..
[47] S. Shariat,et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. , 2004, The Journal of urology.
[48] U. Kim,et al. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[49] M. Aickin,et al. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. , 1996, American journal of public health.
[50] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[51] Aihua Zhang,et al. Cell metabolomics. , 2013, Omics : a journal of integrative biology.
[52] Daniel B. Vigneron,et al. Validation of Hyperpolarized 13 C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor , 2012 .
[53] R. Franklin,et al. Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem , 2009, Prostate Cancer and Prostatic Diseases.
[54] Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.
[55] R. Franklin,et al. Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.